News archive
Showing 700 results
May 2025
-
Story Discovery
How We’re Reimagining Cancer Care for the Next Generation Patient
-
Story Education and Awareness
Addressing Elevated Lipoprotein(a): The Importance of Testing At-Risk Patients
Elevated Lp(a) is a unique and genetically determined condition that can increase risk for ASCVD1. Read on to learn more about patient populations at risk.
-
Media Release
New Novartis data at ASCO and EHA showcase momentum of pioneering portfolio with promising pipeline
NATALEE subanalysis evaluates Kisqali in pre-menopausal early breast cancer patients, amid rising diagnosis rates in younger patients Pluvicto analysis and Scemblix ASC4START primary… -
Story Education and Awareness
Autoimmune Diseases Disproportionately Impact Women — Here’s Why That Matters
Novartis is raising awareness about the disproportionate impact and often invisible burden of autoimmune diseases on women.
April 2025
-
Media Release
Novartis plans to expand its US-based manufacturing and R&D footprint with a total investment of $23B over the next 5 years
Expanded US manufacturing and R&D presence with investment in 10 facilities, including 7 brand new facilities With new manufacturing capacity, Novartis will be able to produce 100% of its… -
Media Release
Novartis receives FDA accelerated approval for Vanrafia® (atrasentan), the first and only selective endothelin A receptor antagonist for proteinuria reduction in primary IgA nephropathy (IgAN)
Vanrafia can be seamlessly added to supportive care in IgAN and used as a foundational therapy with no requirement for a REMS (Risk Evaluation Mitigation Strategy) program1 Phase III data showed…
March 2025
-
Media Release
FDA approves Novartis radioligand therapy Pluvicto® for earlier use before chemotherapy in PSMA-positive metastatic castration-resistant prostate cancer
New indication approximately triples eligible patient population, allowing Pluvicto® to be used after one androgen receptor pathway inhibitor (ARPI) and now before chemotherapy Pluvicto… -
Media Release
Novartis to present new data at AAN, including seven-year disability outcomes and safety analysis of Kesimpta® in people with relapsing multiple sclerosis
Long-term disability and safety data from ALITHIOS open-label extension study on continuous treatment with Kesimpta vs. later switch from teriflunomide in relapsing multiple sclerosis (RMS)… -
Media Release
Novartis receives third FDA approval for oral Fabhalta® (iptacopan) - the first and only treatment approved in C3 glomerulopathy (C3G)
Phase III study showed sustained proteinuria reduction at one year with favorable safety1 Fabhalta is the only oral alternative complement pathway inhibitor thought to target the… -
Media Release
Novartis named first-ever corporate pharmaceutical partner of the National Football League
The long-term, exclusive pharmaceutical category agreement is designed to turn fans' passion for the game into a commitment to better health Novartis sports partnership covers the NFL's marquee… -
Story Education and Awareness
Novartis joins Susan G. Komen in first-of-its-kind breast cancer policy coalition